Evoluzione della chemioresistenza nei batteri patogeni gram-positivi.

Translated title of the contribution: Emergence of drug-resistant gram-positive pathogenic bacteria

A. Marchese, G. C. Schito, E. A. Debbia

Research output: Contribution to journalArticle

Abstract

Staphylococcus aureus is a common cause of soft tissue infection, e.g. impetigo, cellulitis, or wound infection, and causes osteomyelitis, arthritis, bacteremia with metastatic infection, and scalded skin and toxic shock syndromes. Coagulase-negative staphylococci have become increasingly important causes of nosocomial bacteremia associated with invasive monitoring, intravascular catheters and prosthetic heart valves or joints. Most staphylococci produce blactamase and are resistant to penicillin. An increasing proportion of S. aureus have intrinsic resistance to methicillin (MRSA) and present major problems in hospitals for the control of cross infection. The glycopeptides, teicoplanin and vancomycin, are the antibiotics of first choice for treatment of these infections. After the first report describing a Japanese clinical isolate of vancomycin-resistant S. aureus (VRSA), several papers have documented the emergence of these microorganisms. Since the development and spreading of this phenomenon which is perceived as a fearsome threat to the already difficult therapy of nosocomial infections due to the prevalence of heterogeneous vancomycin resistance, we found the incidence of MRSA exceeds 35% in our hospital. Out of 179 methicillin-resistant S. aureus isolated during 1997-1998, two strains (1.1%) gave subclones with vancomycin MICs of 8 mg/L. PFGE showed identical restriction patterns for both isolates, suggesting transfer of a single clone between two different patients.

Original languageItalian
Pages (from-to)12-14
Number of pages3
JournalJournal of Chemotherapy
Volume12 Suppl 2
Publication statusPublished - Jul 2000

Fingerprint

Gram-Positive Bacteria
Vancomycin
Methicillin-Resistant Staphylococcus aureus
Staphylococcus aureus
Cross Infection
Bacteremia
Staphylococcus
Pharmaceutical Preparations
Impetigo
Vancomycin Resistance
Teicoplanin
Soft Tissue Infections
Methicillin Resistance
Cellulitis
Glycopeptides
Coagulase
Heart Valves
Wound Infection
Osteomyelitis
Septic Shock

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)

Cite this

Marchese, A., Schito, G. C., & Debbia, E. A. (2000). Evoluzione della chemioresistenza nei batteri patogeni gram-positivi. Journal of Chemotherapy, 12 Suppl 2, 12-14.

Evoluzione della chemioresistenza nei batteri patogeni gram-positivi. / Marchese, A.; Schito, G. C.; Debbia, E. A.

In: Journal of Chemotherapy, Vol. 12 Suppl 2, 07.2000, p. 12-14.

Research output: Contribution to journalArticle

Marchese, A, Schito, GC & Debbia, EA 2000, 'Evoluzione della chemioresistenza nei batteri patogeni gram-positivi.', Journal of Chemotherapy, vol. 12 Suppl 2, pp. 12-14.
Marchese A, Schito GC, Debbia EA. Evoluzione della chemioresistenza nei batteri patogeni gram-positivi. Journal of Chemotherapy. 2000 Jul;12 Suppl 2:12-14.
Marchese, A. ; Schito, G. C. ; Debbia, E. A. / Evoluzione della chemioresistenza nei batteri patogeni gram-positivi. In: Journal of Chemotherapy. 2000 ; Vol. 12 Suppl 2. pp. 12-14.
@article{62481262c95e477bb16aa7f8959b5cc1,
title = "Evoluzione della chemioresistenza nei batteri patogeni gram-positivi.",
abstract = "Staphylococcus aureus is a common cause of soft tissue infection, e.g. impetigo, cellulitis, or wound infection, and causes osteomyelitis, arthritis, bacteremia with metastatic infection, and scalded skin and toxic shock syndromes. Coagulase-negative staphylococci have become increasingly important causes of nosocomial bacteremia associated with invasive monitoring, intravascular catheters and prosthetic heart valves or joints. Most staphylococci produce blactamase and are resistant to penicillin. An increasing proportion of S. aureus have intrinsic resistance to methicillin (MRSA) and present major problems in hospitals for the control of cross infection. The glycopeptides, teicoplanin and vancomycin, are the antibiotics of first choice for treatment of these infections. After the first report describing a Japanese clinical isolate of vancomycin-resistant S. aureus (VRSA), several papers have documented the emergence of these microorganisms. Since the development and spreading of this phenomenon which is perceived as a fearsome threat to the already difficult therapy of nosocomial infections due to the prevalence of heterogeneous vancomycin resistance, we found the incidence of MRSA exceeds 35{\%} in our hospital. Out of 179 methicillin-resistant S. aureus isolated during 1997-1998, two strains (1.1{\%}) gave subclones with vancomycin MICs of 8 mg/L. PFGE showed identical restriction patterns for both isolates, suggesting transfer of a single clone between two different patients.",
author = "A. Marchese and Schito, {G. C.} and Debbia, {E. A.}",
year = "2000",
month = "7",
language = "Italian",
volume = "12 Suppl 2",
pages = "12--14",
journal = "Journal of Chemotherapy",
issn = "1120-009X",
publisher = "Maney Publishing",

}

TY - JOUR

T1 - Evoluzione della chemioresistenza nei batteri patogeni gram-positivi.

AU - Marchese, A.

AU - Schito, G. C.

AU - Debbia, E. A.

PY - 2000/7

Y1 - 2000/7

N2 - Staphylococcus aureus is a common cause of soft tissue infection, e.g. impetigo, cellulitis, or wound infection, and causes osteomyelitis, arthritis, bacteremia with metastatic infection, and scalded skin and toxic shock syndromes. Coagulase-negative staphylococci have become increasingly important causes of nosocomial bacteremia associated with invasive monitoring, intravascular catheters and prosthetic heart valves or joints. Most staphylococci produce blactamase and are resistant to penicillin. An increasing proportion of S. aureus have intrinsic resistance to methicillin (MRSA) and present major problems in hospitals for the control of cross infection. The glycopeptides, teicoplanin and vancomycin, are the antibiotics of first choice for treatment of these infections. After the first report describing a Japanese clinical isolate of vancomycin-resistant S. aureus (VRSA), several papers have documented the emergence of these microorganisms. Since the development and spreading of this phenomenon which is perceived as a fearsome threat to the already difficult therapy of nosocomial infections due to the prevalence of heterogeneous vancomycin resistance, we found the incidence of MRSA exceeds 35% in our hospital. Out of 179 methicillin-resistant S. aureus isolated during 1997-1998, two strains (1.1%) gave subclones with vancomycin MICs of 8 mg/L. PFGE showed identical restriction patterns for both isolates, suggesting transfer of a single clone between two different patients.

AB - Staphylococcus aureus is a common cause of soft tissue infection, e.g. impetigo, cellulitis, or wound infection, and causes osteomyelitis, arthritis, bacteremia with metastatic infection, and scalded skin and toxic shock syndromes. Coagulase-negative staphylococci have become increasingly important causes of nosocomial bacteremia associated with invasive monitoring, intravascular catheters and prosthetic heart valves or joints. Most staphylococci produce blactamase and are resistant to penicillin. An increasing proportion of S. aureus have intrinsic resistance to methicillin (MRSA) and present major problems in hospitals for the control of cross infection. The glycopeptides, teicoplanin and vancomycin, are the antibiotics of first choice for treatment of these infections. After the first report describing a Japanese clinical isolate of vancomycin-resistant S. aureus (VRSA), several papers have documented the emergence of these microorganisms. Since the development and spreading of this phenomenon which is perceived as a fearsome threat to the already difficult therapy of nosocomial infections due to the prevalence of heterogeneous vancomycin resistance, we found the incidence of MRSA exceeds 35% in our hospital. Out of 179 methicillin-resistant S. aureus isolated during 1997-1998, two strains (1.1%) gave subclones with vancomycin MICs of 8 mg/L. PFGE showed identical restriction patterns for both isolates, suggesting transfer of a single clone between two different patients.

UR - http://www.scopus.com/inward/record.url?scp=0034232023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034232023&partnerID=8YFLogxK

M3 - Articolo

C2 - 11428095

AN - SCOPUS:0034232023

VL - 12 Suppl 2

SP - 12

EP - 14

JO - Journal of Chemotherapy

JF - Journal of Chemotherapy

SN - 1120-009X

ER -